IBA has acquired PhantomX GmbH, enhancing its dosimetry portfolio in healthcare diagnostics and therapeutic systems, including AI quality assurance. PhantomX, known for realistic anthropomorphic phantoms, specializes in AI validation tools for medical imaging globally. The merger aims to advance AI-driven technologies in medical imaging for improved clinical solutions. IBA, a leader in particle accelerator technology, plans to leverage PhantomX’s expertise to provide greater value to clinicians and patients worldwide. Founded in 2018, PhantomX’s technology will now reach new markets under the merger with IBA.

Read more at GlobeNewswire: IBA integrates Artificial Intelligence Quality Assurance